Confidence in Concept 2012 - Liverpool school of Tropical Medicine
Lead Research Organisation:
Liverpool School of Tropical Medicine
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- Liverpool School of Tropical Medicine (Lead Research Organisation)
- Shanghai Institute of Organic Chemistry (SIOC) (Collaboration)
- Shanghai Jiao Tong University (Collaboration)
- Grifols (Collaboration)
- Absolute Antibody Ltd. (Collaboration)
- UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST (Collaboration)
- UNIVERSITY OF LEEDS (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- Oslo University Hospital (Collaboration)
- Guangdong University of Technology (Collaboration)
- Vietnam Academy of Science and Technology (Collaboration)
- Centers for Disease Control and Prevention (CDC) (Collaboration)
- UCB Pharma (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Syngenta International AG (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Heinrich Heine University Düsseldorf (Collaboration)
- The Global Alliance for TB Drug Development (Collaboration)
- Vietnam National Lung Hospital (Collaboration)
- Abaxon Biologics (Collaboration)
- Liverpool School of Tropical Medicine (Collaboration)
- Vietnam National University (Collaboration)
- AMR Centre (Collaboration)
People |
ORCID iD |
Publications
Aljayyoussi G
(2016)
OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.
in Malaria journal
Antoine T
(2014)
Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential.
in The Journal of antimicrobial chemotherapy
Bangert M
(2012)
P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.
in The Journal of infectious diseases
Bangert M
(2013)
Immunoactivating peptide p4 augments alveolar macrophage phagocytosis in two diverse human populations.
in Antimicrobial agents and chemotherapy
Blundell P
(2019)
A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.
in Methods in molecular biology (Clifton, N.J.)
Blundell PA
(2019)
Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus.
in Journal of immunology (Baltimore, Md. : 1950)
Blundell PA
(2017)
Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
in The Journal of biological chemistry
Bos L
(2016)
ESICM LIVES 2016: part one Milan, Italy. 1-5 October 2016
in Intensive Care Medicine Experimental
Charoensutthivarakul S
(2015)
2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties
in MedChemComm
Copple IM
(2012)
Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials.
in Molecular medicine (Cambridge, Mass.)
| Description | Macrofilaricide Drug Accelerator (MacDA) 2015 to date |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Member of the MMV External Scientific Advisory Board (2008 to 2012) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Steering committee for an EU TB drug discovery consortium |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | • UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites" - 2014- to date |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | http://www.costcm1307.org/CM1307/Home.html |
| Description | Alder Hey Children's Charity |
| Amount | £9,791 (GBP) |
| Organisation | Alder Hey Children's NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 06/2018 |
| Description | BMGF |
| Amount | $3,491,050 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 03/2016 |
| End | 12/2017 |
| Description | CEIDR Translational Pump Priming |
| Amount | £45,435 (GBP) |
| Organisation | Centre for Excellence in Infectious Disease Research Innovations |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2020 |
| Description | Clinical Research Career Development Fellowship: "When is enough, enough? Physiological responses to fluid resuscitation in sub-Saharan African adults with sepsis" |
| Amount | £813,000 (GBP) |
| Funding ID | 211098 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2021 |
| Description | Grifols Investigator Lead Award |
| Amount | $70,000 (USD) |
| Organisation | Grifols |
| Sector | Private |
| Country | Global |
| Start | 12/2012 |
| End | 10/2014 |
| Description | Horizon 2020 anti-microbial stewardship |
| Amount | € 3,600,000 (EUR) |
| Funding ID | BreathSpec device |
| Organisation | European Commission |
| Department | Horizon 2020 |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2018 |
| End | 03/2019 |
| Description | IMI EU FP7 "Model-based preclinical development of anti-tuberculosis drug combinations" |
| Amount | € 478,278 (EUR) |
| Funding ID | 115337 |
| Organisation | European Commission |
| Department | Seventh Framework Programme (FP7) |
| Sector | Public |
| Country | European Union (EU) |
| Start | 05/2012 |
| End | 04/2017 |
| Description | Innovate UK |
| Amount | £635,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Intensive Care Society New Investigator Award |
| Amount | £10,791 (GBP) |
| Funding ID | SU9AGB |
| Organisation | Intensive Care Foundation (ICF) |
| Sector | Private |
| Country | Australia |
| Start | 07/2017 |
| End | 07/2018 |
| Description | Liverpool Health Partners Pump Priming Award |
| Amount | £40,000 (GBP) |
| Organisation | Liverpool Health Partners |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2013 |
| End | 02/2015 |
| Description | MRC CiC - AAV-vectored delivery of engineered monoclonal antibodies as a prophylactic strategy against bloodstage malaria |
| Amount | £38,574 (GBP) |
| Funding ID | not known |
| Organisation | Liverpool School of Tropical Medicine |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 02/2022 |
| Description | MRC DPFS |
| Amount | £602,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 03/2017 |
| Description | MRC newton Vietnam |
| Amount | £399,449 (GBP) |
| Funding ID | MR/N028376/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2018 |
| Description | Patent license fee for HexaGard |
| Amount | £100,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2012 |
| End | 05/2018 |
| Description | Pathfinder |
| Amount | £139,400 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 07/2017 |
| Description | Redx Pharma PLC |
| Amount | £98,000 (GBP) |
| Organisation | Redx Pharma Plc |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 07/2022 |
| Description | SBRI Vaccines for Global Epidemics - Preclinical Stage 1 |
| Amount | £382,974 (GBP) |
| Funding ID | 87113-544156 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 05/2018 |
| Description | UCB Pharma Research Grant |
| Amount | £40,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 05/2017 |
| Description | UCB Pharma Research Grant |
| Amount | £100,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 01/2016 |
| Description | Wellcome Trust - Multi-User Equipment Grant |
| Amount | £600,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2019 |
| Description | Wellcome Trust ISSF |
| Amount | £72,000 (GBP) |
| Organisation | Liverpool School of Tropical Medicine |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 03/2016 |
| Description | Wellcome Trust Innovator Award |
| Amount | £484,578 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2019 |
| Title | GFP-Mycobacterium tuberculosis |
| Description | We have generated a stable GFP-transformed Mtb. This allows the real-time monitoring of Mtb using fluorescence-based technologies. |
| Type Of Material | Cell line |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | The GFP-tagged Mtb allows the investigator to "follow" the Mtb infection, replication and viability in a variety of model systems, e.g. intracellular systems, whole blood assay etc. |
| Title | Glycan ELISA |
| Description | Novel ELISA to detect binding to glycan receptors |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Understanding that antibodies can interact with a greater number of receptors than previously thought |
| URL | https://link.springer.com/protocol/10.1007%2F978-1-4939-8958-4_20 |
| Title | High-content imaging platform for intracellular M. tuberculosis |
| Description | We have set up a high-content imaging platform for the measurement of intracellular M. tuberculosis. A clinically significant sub-population of Mtb is found inside host cells, e.g. macrophages. Using our HC platform we are now able to identify drugs that are active against this sub-population. This platform will have significant utility in identifying drugs that can treat drug persistent Mtb. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | This system is currently being evaluated as an improved in vitro system for the clinical prediction of drug activity. If found to be predictive, this system is likely to be incorporated into drug discovery pipelines used by industry and academia. |
| Title | Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens' |
| Description | Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens' We have set up to our knowledge the first dedicated HG3 imaging facility, able to sort and image HG3 pathogens, e.g. TB and HIV |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | It has just been set up, impact will be described next year |
| Title | Whole blood phagocytosis assay |
| Description | We developed this assay to measure neutrophil function in whole blood. This was initially done to measure the effect of P4 peptide on phagocytic function but has since be utilised by multiple different partners to measure neutrophil function in a variety of different ways (including neutrophil function after chemotherapy, neutrophil function in response to histone toxins and neutrophil function in paediatric patients) |
| Type Of Material | Biological samples |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Through this method we have established multiple partnerships with institutions at UoL, Alder Hey, Malawi Liverpool-Wellcome Trust Clinical Research Centre and Cambridge. These collaborations all have active research projects using the assay that will should come to fruition in the form of published manuscripts in the next couple of years. |
| Title | enose technology |
| Description | Collects organic volatile compounds - the headspace (air above the sample or just air in the case of breath) is pulled through the instruments in a controlled fashion and the instrument response to that sample recorded. |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | Ability to run samples in UHCW in cat III lab to profile organic compounds produced by disease |
| Title | OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens |
| Description | Background The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made. Methods An internet-based tool has been developed using STELLA® software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds. Results The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies. Conclusions OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool. |
| URL | http://optimalpk.lstmed.ac.uk |
| Description | AMR Centre |
| Organisation | AMR Centre |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We are currently in discussion on industrial partnership to take P4 peptide forward to FIH studies. |
| Collaborator Contribution | Currently in negotiation under NDA |
| Impact | Nil yet |
| Start Year | 2019 |
| Description | Absolute Antibody |
| Organisation | Absolute Antibody Ltd. |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have made novel constructs based on our MRC CiC award that we have now under MTA provided to Absolute Antibody. They will now try and functionalism our molecules with an aim to develop new diagnostics. |
| Collaborator Contribution | See above |
| Impact | We have made novel constructs based on our MRC CiC award that we have now under MTA provided to Absolute Antibody. They will now try and functionalism our molecules with an aim to develop new diagnostics. |
| Start Year | 2015 |
| Description | Access to Syngenta Compunds |
| Organisation | Syngenta International AG |
| Department | Syngenta Ltd (Bracknell) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | An agreement has been reached with Sygnenta for us to gain access and screen numerous compounds for anti infective activity |
| Collaborator Contribution | Syngenta have agreed to provide up to 0.5million compounds for screening as potential antimalarial starting points and they have given us access to the structures to continue and enhance our research in this area. |
| Impact | Still in progress |
| Start Year | 2013 |
| Description | Astra Zeneca repurposing drugs |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Assessing anti infective potential of AZ repurposing molecules. |
| Collaborator Contribution | Provision of compounds for testing |
| Impact | Still in progress |
| Start Year | 2012 |
| Description | Collaborating with Abaxon Biologics |
| Organisation | Abaxon Biologics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discussion are on-going with licensing monomeric-Fc patents covering new therapies for neurology |
| Collaborator Contribution | Due diligence |
| Impact | None as yet |
| Start Year | 2018 |
| Description | Developing blockers of Zika infection |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with Professor Alain Kohl |
| Collaborator Contribution | Will test our hypersialyaletd Fc fragments at controlling viruses |
| Impact | none yet |
| Start Year | 2019 |
| Description | Fc-vaccines for Zika |
| Organisation | University of Liverpool |
| Department | Institute of Infection and Global Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are developing Zika vaccines using Fc-fusion technology developed in our laboratory. |
| Collaborator Contribution | Lance Turtle contributed expertise on neutralisation assays for antibodies raised by vaccines to Zika |
| Impact | None as yet |
| Start Year | 2017 |
| Description | Glycomic characterisation of the IgG1-Fc glycan |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Determine glycan structures on our Fc-molecules |
| Collaborator Contribution | Stuart Haslam determined the glycan structures |
| Impact | Publication |
| Start Year | 2018 |
| Description | Guangdong University of Technology, China (GDUT) |
| Organisation | Guangdong University of Technology |
| Country | China |
| Sector | Academic/University |
| PI Contribution | We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the " Liverpool-Guangzhou drug discovery joint laboratory", located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium. |
| Collaborator Contribution | We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the " Liverpool-Guangzhou drug discovery joint laboratory", located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium. |
| Impact | Compounds have been synthesised and teaching programs are being developed by the consortium |
| Start Year | 2014 |
| Description | Hypersialylated Fcs for the treatment of antibody-mediated CNS demyelination and microglial activation |
| Organisation | Heinrich Heine University Düsseldorf |
| Department | Institute of Neuropathology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | We have made novel glycosylated Fc fragments to replace IVIg in the treatment of demyelination |
| Collaborator Contribution | Provide a ex-vivo model of neurodegeneration |
| Impact | none yet |
| Start Year | 2018 |
| Description | Hypersialylated blockers of Zika virus (ZIKV) infectivity and neuropathology. |
| Organisation | University of Glasgow |
| Department | Institute of Infection, Immunity and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are testing hypersialylated Fc molecules for controlling Zika mediated neurodegeneration |
| Collaborator Contribution | Provide virus models of neural degeneration |
| Impact | too early |
| Start Year | 2018 |
| Description | Imperial College |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We made Fc-proteins |
| Collaborator Contribution | Our partners characterised the glycans on these molecules |
| Impact | papers |
| Start Year | 2012 |
| Description | Jenner Institute |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have designed new constructs for delivering antigens in malaria vaccines. |
| Collaborator Contribution | The Jenner will test the immunogenicity of these constructs in animal models of malaria |
| Impact | None as yet |
| Start Year | 2014 |
| Description | Neutrophil bead assay: Use in sepsis and concomitant HIV |
| Organisation | Liverpool School of Tropical Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have facilitated this project through common recruitment and use of staff to screen participants and enrol to the studies. We have acted as local (Malawi) lead for the project, including administrative support and ethical review. |
| Collaborator Contribution | Research concept and assay have been developed by the collaborators. Training of local laboratory staff has been done through a site visit provided by the postdoctoral scientist form the project. SOPs have been contributed, and costs for the assay and sample collection are wholly funded by the collaborator. |
| Impact | SOPs and assay QA procedures have been defined, and submitted for publication (under review). Ethics approval for sample collection has been given. |
| Start Year | 2017 |
| Description | P4 collaboration group for DPFS bid |
| Organisation | Centers for Disease Control and Prevention (CDC) |
| Department | Bacterial Pathogenesis |
| Country | United States |
| Sector | Public |
| PI Contribution | We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide. |
| Collaborator Contribution | CDC Atlanta provide P4 and intellectual input ITU teams recruit patients We collect samples Our lab and Kadioglu lab run assays ex vivo. |
| Impact | We have been shortlisted for a DPFS award |
| Start Year | 2012 |
| Description | P4 collaboration group for DPFS bid |
| Organisation | Grifols |
| Department | Research and Development |
| Country | United States |
| Sector | Private |
| PI Contribution | We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide. |
| Collaborator Contribution | CDC Atlanta provide P4 and intellectual input ITU teams recruit patients We collect samples Our lab and Kadioglu lab run assays ex vivo. |
| Impact | We have been shortlisted for a DPFS award |
| Start Year | 2012 |
| Description | P4 collaboration group for DPFS bid |
| Organisation | University of Liverpool |
| Department | Institute of Infection and Global Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide. |
| Collaborator Contribution | CDC Atlanta provide P4 and intellectual input ITU teams recruit patients We collect samples Our lab and Kadioglu lab run assays ex vivo. |
| Impact | We have been shortlisted for a DPFS award |
| Start Year | 2012 |
| Description | Shanghai Institute of Organic Chemistry (SIOC.) |
| Organisation | Shanghai Institute of Organic Chemistry (SIOC) |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical. |
| Collaborator Contribution | Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical. |
| Impact | Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical. |
| Start Year | 2014 |
| Description | Shanghai Jiao Tong University |
| Organisation | Shanghai Jiao Tong University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | We make mutant Fcs and oligomeric Fc |
| Collaborator Contribution | Our partners use state of the art cryo Atomic Force Microscopy to image the molecules we make |
| Impact | Papers, more research |
| Start Year | 2012 |
| Description | TB Alliance |
| Organisation | The Global Alliance for TB Drug Development |
| Country | Global |
| Sector | Private |
| PI Contribution | We have developed inhibitors via the MRC funded project that are at lead stage - these are being tested presently. We are also in discussions with TBA regarding our high content imaging platform, the development of which is supported via a MRC CiC award |
| Collaborator Contribution | TBAlliance have conducted in vivo PK studies on our lead compounds and we will shortly be conducting in vivo drug efficacy experiments using their TB drug development network If successful this will form the basis of a more extensive drug development programme |
| Impact | TBAlliance are providing support in the way of in vivo PK and TB in vivo drug efficacy models (rodent acute model) If successful this will form the basis of a more extensive drug development programme |
| Start Year | 2014 |
| Description | UCB Pharma |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | As a consequence of MRC CIC investment we are in the process of licensing two patents and a trademark to UCB Pharma. Under the joint agreement UCB Pharma are funding an 18 month project to develop the prototype molecule. |
| Collaborator Contribution | see above |
| Impact | The joint agreement is still under review |
| Start Year | 2013 |
| Description | University of Leeds |
| Organisation | University of Leeds |
| Department | School of Physics and Astronomy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have cloned adhirons from Leeds onto our hexa-Fc platform. And developed novel adhirons specific for pneumolysin with which to treat meningitis |
| Collaborator Contribution | Provided the adhiron sequences |
| Impact | In process |
| Start Year | 2014 |
| Description | University of Oslo |
| Organisation | Oslo University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | We made mutant proteins |
| Collaborator Contribution | Our partners investigated the interaction of our mutant proteins to FcRn |
| Impact | Papers |
| Start Year | 2012 |
| Description | University of Warwick |
| Organisation | University Hospitals Coventry and Warwickshire NHS Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We developed mutated Fc-proteins |
| Collaborator Contribution | Our collaborator at Warwick investigated interactions with DC-SIGN |
| Impact | Papers |
| Start Year | 2012 |
| Description | Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam |
| Organisation | Vietnam Academy of Science and Technology |
| Country | Viet Nam |
| Sector | Academic/University |
| PI Contribution | This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam |
| Collaborator Contribution | The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme. |
| Impact | Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017. |
| Start Year | 2015 |
| Description | Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam |
| Organisation | Vietnam National Lung Hospital |
| Country | Viet Nam |
| Sector | Hospitals |
| PI Contribution | This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam |
| Collaborator Contribution | The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme. |
| Impact | Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017. |
| Start Year | 2015 |
| Description | Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam |
| Organisation | Vietnam National University |
| Country | Viet Nam |
| Sector | Academic/University |
| PI Contribution | This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam |
| Collaborator Contribution | The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme. |
| Impact | Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017. |
| Start Year | 2015 |
| Title | CHIMERIC FC RECEPTOR BINDING PROTEINS AND USES THEREOF |
| Description | The present invention relates to chimeric proteins, to compositions comprising such proteins and to the medical uses of such proteins and compositions. In particular the proteins or compositions of the invention may be used in the prevention or treatment of autoimmune diseases or inflammatory diseases, or for the prevention or treatment of diseases mediated through binding of sialic acid dependent receptors, or as vaccines or as anti-cancer agents. One aspect of the invention relates to a chimeric Fc receptor binding protein which comprises two chimeric polypeptide chains, wherein each chimeric polypeptide chain comprises an immunoglobulin G heavy chain constant region, a tailpiece region and a hinge region, wherein the amino acid sequence of each polypeptide chain possess a sugar moiety at or close to the N-terminus and a sugar moiety at or close to the C- terminus, and their use in the treatment or prevention of a disease mediated by a pathogen that relies on sialic acid receptors interactions. |
| IP Reference | WO2019175605 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | Currently in negotiations for licensing |
| Title | FUSION PROTEIN COMPRISING MULTIPLE HINGE SEQUENCES |
| Description | The invention relates to fusion polypeptides derived from IgG. The fusion polypeptides comprise a domain derived from an immunoglobulin heavy chain constant region; and a plurality of hinge regions derived from IgG hinge sequences. The invention also relates to nucleic acids encoding the fusion polypeptides, and to proteins comprising two fusion polypeptides of the invention. Also provided are a pharmaceutical composition comprising a fusion polypeptide and/or protein of the invention, and medical uses of the polypeptides, proteins, or compositions. |
| IP Reference | WO2019175606 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | New approaches to deliver antigens that don't interfere with receptor binding |
| Title | HexaGard UK00003018151 |
| Description | A drug name for hexameric Fc fusion |
| IP Reference | |
| Protection | Trade Mark |
| Year Protection Granted | 2013 |
| Licensed | Yes |
| Impact | This patent has been licensed to UCB Pharma for further development and they are talking it into national phase. We now collaborate with UCB Pharma |
| Title | IMMUNOMODULATORY PROTEINS |
| Description | A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. |
| IP Reference | US2018362600 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | To UCB pharma from 2015-2017. To be licensed to CSL Behring from mid 2019 |
| Title | IMMUNOMODULATORY PROTEINS |
| Description | A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. |
| IP Reference | WO2014060712 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | Yes |
| Impact | Non-exclusively licensed to UCB Pharma Patent has now been granted unopposed in Europe |
| Title | MONOMERIC PROTEINS AND USES THEREOF |
| Description | Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use. |
| IP Reference | WO2017191439 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Publication see Journal of Immunology 2018 |
| Title | Murine antibodies |
| Description | A mouse fusion protein comprising two chimeric polypeptide chains each comprising two murine IgG heavy chain chains having an immunoglobulin tailpiece from, or derived from, a non-native immunoglobulin and wherein the amino acid sequence of each of the IgG heavy chain constant regions comprises an amino acid modification (e.g. M84C) which promotes the multimerisation or polymerisation of the fusion protein. Preferably the tailpiece is human and is derived from IgM or IgA and has a substitution or deletion at residue C17. Preferably, each chimeric chain comprises one or more murine hinge regions and a targeting moiety such as an ntigen binding region, small molecule or nucleic acid. The invention further relates to the uses of the fusion protein to detect a target molecule in a sample, preferably as a means for diagnosis such as blood group haemagglutination. |
| IP Reference | GB2572008 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | none as yet |
| Title | POLYMERIC PROTEINS AND USES THEREOF |
| Description | Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable formedical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins. |
| IP Reference | WO2016009232 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | N/A |
| Title | Enose |
| Description | Data collection of organic compounds. The headspace (air above the sample or just air in the case of breath) is pulled through the instruments in a controlled fashion and the instrument response to that sample recorded. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | If successful in clinical trials will be able to convert tool to a handheld machine for diagnosis in rural settings |
| Title | HexaGard |
| Description | We have licensed patents related to this molecule with UCB Pharma. We are now collaborating with UCB to refine the molecule towards pre-clinical development |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | A collaborative project with UCB Pharma |
| URL | http://immunologynews.blogspot.co.uk/2013/11/generating-alternative-to-ivig-therapy.html |
| Title | New Drug against TB |
| Description | Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2010 |
| Development Status | Under active development/distribution |
| Impact | Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy. The lead series have a novel mode of action. |
| Title | New drug against malaria |
| Description | New drug target against malaria identified. There are several projects under way from hit identification to late leads. These projects are in collaboration with GSK and AZ and involve MMV (malaria PDP). |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2008 |
| Development Status | Under active development/distribution |
| Impact | New drug target against malaria identified. There are several projects under way from hit identification to late leads. These projects are in collaboration with GSK and AZ and involve MMV (malaria PDP). |
| URL | http://mmv.org |
| Title | Phase 1 Clinical Trial Authorisation Application |
| Description | Following on from the MRC CiC award we established that P4 peptide effectively increased neutrophil activity in cells taken from patients on the ITU with severe infection. We used this information to successfully apply for a MRC DPFS award to fund pre-clinical toxicology studies in rats and dogs. Now, having successfully completed this project, we were invited to apply for a full application to the MRC DPFS scheme to fund a phase 1 clincial trial at the Royal Liverpool Univeristy Hospital (panel meeting is 20th September). |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | N/A, see above |
| Description | Barcelona Grifols ISR meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Aiming to engage commercial sponsorship in research with MRC help DPFS 2014 application |
| Year(s) Of Engagement Activity | 2014 |
| Description | CDC visit to LSTM and UoL |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Ed Ades from CDC visited the UK, spoke in Leicester, Univ of Liverpool and UoL. P4 project grew as a result, now approaching DPFS application. Further grants (e.g. Grifols sponsorship) and then DPFS application (rated fundable but not funded in 2013). |
| Year(s) Of Engagement Activity | 2012 |
| Description | European Society of Intensive Care Medicine Conference Presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of work funded by MRC CiC 2012 ward. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.esicm.org/news-article/promo-reminder-abstract-submission-LIVES-2016 |
| Description | Glycan engineering for vaccines presented at Pirbright |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | BSI frontiers in human immunology antibody discovery |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.immunology.org/events/frontiers-in-human-and-veterinary-antibody-discovery |
| Description | HOWSTUFFWORKS |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Viking Toilet Worm Investigation Finds Genetic Clues to Emphysema's Origins |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://now.howstuffworks.com/2016/02/12/viking-toilet-investigation-emphysema#! |
| Description | Human Challenge Models workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lancet Infectious Diseases report as per papers MRC Programme grant Expt Human Pneumococcal Carriage funded Nov 2014 |
| Year(s) Of Engagement Activity | 2013 |
| Description | IFLS Blog - Viking Worm Infestation May Provide Genetic Link To Modern Lung Disease |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Viking Worm Infestation May Provide Genetic Link To Modern Lung Disease Blog |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.iflscience.com/health-and-medicine/viking-worm-infestation-may-provide-genetic-link-moder... |
| Description | ITU conference 2013 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented to ITU clinicians and have now engaged 2 ITU teams in P4 research. ITU groups now welcome phase 2 study. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Institutional visit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited Speaker at the University of Saarland, Saarbrucken, Germany |
| Year(s) Of Engagement Activity | 2017 |
| Description | Institutional visit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited Speaker at the Helmholtz Centre for Infection Research in Braunschweig, Germany |
| Year(s) Of Engagement Activity | 2017 |
| Description | International Conference |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Invited Speaker 19th May 2018. 11th International Congress on Autoimmunity. Lisbon. Invited by Fabian Kasermann CSL Behring. N-terminal hinge glycosylation brings novel receptor binding properties to human IgG1-Fc multimers and monomers. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://autoimmunity.kenes.com/2018#.W8CDcS2ZNBy |
| Description | Invited Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | 19th September 2018. IITM Perspectives Meeting: Biologics as Therapeutics. Invited by Profs. Chris Tang and Helen McShane. University of Oxford. N-terminal hinge glycosylation for novel receptor interactions of IgG Fc monomers and multimers . University of Oxford doctoral training programme. I provided the wisdom of my experience about translating research. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://iitmoxford.files.wordpress.com/2018/09/booklet_iitm_symposium-2018.pdf |
| Description | Invited Speaker - Antibiotic Discovery UK Ltd, London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Talk followed by Q&A session n/a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Invited Speaker at the "Closing the Global Health Divide through Partnership Driven Innovation Meeting" |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&D for infectious diseases. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Invited Speaker at the 2014 Towards New Therapeutics for Diseases of the Developing World Conference, Spain |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Talk sparked Q&A session and discussion afterwards n/a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Manchester Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | October 2013 Manchester Science Festival at MOSI took part in 'I'm a scientist, talk to me' with Science Grrl. Over 100,000 attendees for the festival. Spoke to children and adults, mainly 5 -17 years old. not known |
| Year(s) Of Engagement Activity | 2013 |
| Description | Mental Floss Blog |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Link made between emphysema, worm infections and Vikings |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://mentalfloss.com/article/77110/vikings-parasites-may-have-led-lung-problems-their-modern-desce... |
| Description | P4 CIC - ICUsteps |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | We have engaged with ICUsteps, a national organisation that supports ex-critical care patients recovering after critical illness. Members of this organisation have advised in preparation of the Sepsis project and also for submission of the fellowship proposal |
| Year(s) Of Engagement Activity | 2015 |
| Description | Plenary Speaker at the Joint International Tropical Medicine Meeting (JITMM), Thailand |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | 200+ attendees, mainly academics and pharma n/a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Press Release - New Centre for Drugs and Diagnostics |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Type Of Presentation | Paper Presentation |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Press release of the new LSTM Centre for Drugs and Diagnostics A breakfast launch meeting was hosted at the British Society for Parasitology in Nest Gardens, 2013 with 20+ representatives of Small-Medium Enterprises |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.lstmliverpool.ac.uk/about-lstm/news-and-media/latest-news/launch-of-the-lstm-research-cen... |
| Description | Radio Show SciFri |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | I spoke on BBC Radio Merseyside on their SciFri programme on the Breathspec device and new recruitment starting at several hospitals and GP surgeries across the region. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Radio interview |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | local and regional radio interviews public engagement |
| Year(s) Of Engagement Activity | 2013 |
| Description | School Visit (Chester) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | 60 children attended - this was a presentation by me and interactive sessions with the children and teachers. My visit was discussed by the headmaster at the whole school level and was reported to governors and in local news. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Science Festival - Lancashire |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | June 2013 the Lancashire Science Festival at UCLAN took part in 'I'm a scientist, talk to me' with Science Grrl. 2500 attendees of all ages, spoke to mainly children aged 4-12. not known |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://sciencegrrl.co.uk/lancashire-science-festival/ |
| Description | Series of Rational Drug Discovery lectures (Undergraduate) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | To provide a better understanding how the students can translate their science / research activities to have more impact in terms of generating and developing products such as drugs, insecticides etc. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Series of rational drug discovery lectures (Post Graduate) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | To provide a better understanding how the students can translate their science / research activities to have mor eimpact in terms of generating and developing products such as drugs, insecticides etc. |
| Year(s) Of Engagement Activity | 2018 |
| Description | new anti-influenza drugs highlighted by Science Daily |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | https://www.sciencedaily.com/releases/2019/01/190125120114.htm |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.sciencedaily.com/releases/2019/01/190125120114.htm |
| Description | presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Paper Presentation |
| Geographic Reach | Local |
| Primary Audience | Health professionals |
| Results and Impact | WIDER group on Enose technology Networking opportunity |
| Year(s) Of Engagement Activity | 2013 |